XML 17 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

License agreements - Novartis (Details) - USD ($) $ in Thousands	1 Months Ended					3 Months Ended								12 Months Ended			122 Months Ended
	Apr. 30, 2016	Sep. 30, 2014	Jan. 31, 2010	Dec. 31, 2009	Nov. 30, 2009	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
License agreements
Revenues						$ 579,389	$ 551,581	$ 529,932	$ 497,857	$ 528,402	$ 449,683	$ 521,516	$ 382,282	$ 2,158,759	$ 1,881,883	$ 1,536,216
Europe
License agreements
Revenues														90,000	79,900	66,900
U.S.
License agreements
Revenues														2,100,000	1,800,000	1,500,000
JAKAFI
License agreements
Revenues														1,684,968	1,386,964	1,133,392
Novartis
License agreements
Upfront and immediate milestone payment to be received under license agreement					$ 210,000
Upfront payment received under license agreement				$ 150,000
Immediate milestone payment received under license agreement			$ 60,000
Revenues														0	60,000	65,000
Reimbursable costs included in accounts receivable						400				700				400	700		$ 400
Research and development expenses reimbursed														1,500	3,200	3,000
Product royalties in accounts receivable						65,000				55,400				65,000	55,400		65,000
Novartis | Pre-specified Events | Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					1,200,000
Novartis | Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																	132,000
Novartis | Development Milestones | Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					174,000
Novartis | Regulatory Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																	215,000
Novartis | Regulatory Milestones | Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					495,000
Novartis | Commercialization Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone																	120,000
Novartis | Commercialization Milestones | Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement					$ 500,000
Novartis | GVHD | Development Milestones | Phase III
License agreements
Amount recognized and received for the achievement of a predefined milestone																25,000
Novartis | GVHD | Development and Regulatory Milestones | Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement	$ 75,000
Novartis | JAKAFI | U.S.
License agreements
Revenues														77,600	63,000	50,500
Royalties payable						$ 50,200				$ 18,600				50,200	18,600		$ 50,200
Novartis | JAKAVI
License agreements
Revenues														$ 225,900	194,700	151,700
Novartis | JAKAVI | Minimum
License agreements
Royalty payments on future global net sales (as a percent)														12.00%
Novartis | JAKAVI | Maximum
License agreements
Royalty payments on future global net sales (as a percent)														14.00%
Novartis | JAKAVI | Regulatory Milestones | Europe
License agreements
Amount recognized and received for the achievement of a predefined milestone		$ 60,000
Novartis | JAKAVI | Commercialization Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone															60,000	40,000
Revenues															$ 900,000	$ 600,000

X

- Definition

Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementImmediateMilestonePaymentReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents reimbursable costs pertaining to license agreements.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementReimbursableCosts
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents reimbursed costs pertaining to research and development expenses.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementResearchAndDevelopmentReimbursedCost
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the upfront and immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents the upfront payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePayments
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of royalties payable.

+ References

No definition available.

+ Details

Name:	incy_RoyaltiesPayable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the royalty payment receivable under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_RoyaltyPaymentReceivable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_JAKAFIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_GvhdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=incy_JakaviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: